ARCA biopharma, Inc. Form 8-K/A June 11, 2015 **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A **CURRENT REPORT** Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2015 (June 10, 2015) ARCA biopharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-22873 36-3855489 (State or Other Jurisdiction (Commission File Number) (I.R.S. Employer of Incorporation) Identification No.) 11080 CirclePoint Road, Suite 140, Westminster, CO 80020 (Address of Principal Executive Offices) (Zip Code) (720) 940-2200 (Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- £Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- £Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- £Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- £Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### **EXPLANATORY NOTE**

This Current Report on Form 8-K/A (this "Amendment") is being filed as an amendment to the Current Report on Form 8-K filed by ARCA biopharma, Inc. on June 11, 2015 (the "Original Report") with the U.S. Securities and Exchange Commission. The sole purpose of this Amendment is to furnish amended Exhibit 10.1. Accordingly, this Amendment consists only of the facing page, this explanatory note, the Exhibit Index disclosed in Item 9.01 and Exhibit 10.1.

Section 9 — Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number Description

Securities Purchase Agreement by and among the Company and the purchasers identified therein,

dated June 10, 2015

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 11, 2015

ARCA biopharma, Inc. (Registrant)

By:/s/ Brian L. Selby Name: Brian L. Selby

Title: VP, Finance and Chief Accounting Officer

### INDEX TO EXHIBITS

Exhibit

Number Description

Securities Purchase Agreement by and among the Company and the purchasers identified therein,

dated June 10, 2015